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Abstract Glyoxal (GO) and methylglyoxal (MGO) are reac-
tive dicarbonyl compounds formed during autoxidation of both
carbohydrates and lipids. They may react with lysine and
arginine residues of proteins in Maillard or browning reactions,
yielding advanced glycation or lipoxidation end products. Among
these are the imidazolium crosslinks, N,N(-di(NO-lysino))imida-
zolium (glyoxal-lysine dimer, GOLD) and N,N(-di(NO-lysino))-
4-methyl-imidazolium (methylglyoxal-lysine dimer, MOLD).
We have detected and measured GOLD and MOLD in human
serum by electrospray ionization/mass spectrometry/mass spec-
trometry (ESI/MS/MS), using 15N4-GOLD and 15N4-MOLD
as internal standards. In this report we show that levels of GOLD
and MOLD are significantly elevated (3^4-fold, P6 0.01) in
sera of non-diabetic uremic patients, compared to age-matched
controls, and represent a major class of non-enzymatic, Maillard
reaction crosslinks in plasma proteins. These results provide
strong evidence for increased non-enzymatic crosslinking of
tissue proteins by GO and MGO in uremia, implicating oxidative
stress and resultant advanced glycation and lipoxidation reac-
tions in tissue damage in uremia.
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1. Introduction
Advanced glycation and lipoxidation end products (AGEs,
ALEs) are formed non-enzymatically during Maillard or
browning reactions of proteins with reducing sugars or lipid
peroxidation products [1,2]. AGEs and ALEs accumulate in
long-lived tissue proteins, such as collagens and lens proteins,
and are thought to have a role in the development of pathol-
ogy in aging [3], diabetes [4,5], vascular disease [6] and chronic
renal failure [7]. In previous work, we have shown by both
ELISA and chemical assays that protein-bound AGEs or
ALEs, including NO-(carboxymethyl)lysine (CML) [8,9], pyr-
raline [10], pentosidine [11] and malondialdehyde-lysine (un-
published) are increased in serum proteins of uremic and he-
modialysis patients, suggesting a relationship between
advanced glycation and lipoxidation reactions and the patho-
physiology of renal disease.
Reactive dicarbonyl compounds, such as glyoxal (GO) and
methylglyoxal (MGO), are critical intermediates in the chem-
ical modi¢cation of proteins during autoxidation of reducing
sugars and polyunsaturated fatty acids [1,2,12]. Thornalley
has reported increased levels of the MGO in blood in diabetes
and has proposed that MGO is not only an important medi-
ator of tissue damage in diabetes, atherosclerosis, oxidative
stress and aging, but that MGO-modi¢ed proteins are also
recognized by macrophage receptors involved in removal of
modi¢ed proteins from the body [13]. Although the majority
of products remain uncharacterized, reaction of GO and
MGO with proteins leads to formation of imidazolone ad-
ducts [13,14] and NO-(carboxyalkyl)lysines, such as CML
[15^17] and the homologous compound NO-(carboxyethyl)ly-
sine (CEL) [18]. In model systems, Wells-Knecht and col-
leagues also identi¢ed the imidazolium crosslinks known as
glyoxal-lysine dimer (GOLD) and methylglyoxal-lysine dimer
(MOLD) [19,20] (insets to Fig. 1). More recently, Nagaraj et
al. [21] reported the identi¢cation of MOLD in human serum
and detected increased levels of MOLD in serum of diabetic
patients using an HPLC method.
In this report we describe a more speci¢c and selective
electrospray ionization/mass spectrometry/mass spectrometry
(ESI/MS/MS) procedure for simultaneous measurement of
both GOLD and MOLD in serum proteins, and report that
both of these compounds are present in human serum pro-
teins, that they are present at similar concentrations, that they
are signi¢cantly increased in serum of uremic and hemodial-
ysis patients, and that GOLD and MOLD represent the major
non-enzymatic crosslinks in serum proteins in uremia. We
propose that increased chemical modi¢cation of serum and
tissue proteins by dicarbonyl compounds may be important
in the pathogenesis of vascular disease in uremia.
2. Materials and methods
2.1. Preparation of standards
15N4-GOLD and 15N4-MOLD were synthesized from 15N2-formyl-
lysine (15N2-fL), prepared by reaction of 15N2-lysine with acetic anhy-
dride and formic acid, as described by Hofmann et al. [22]. To prepare
15N4-GOLD, 15N2-fL (9 mg, 50 mmol) was added to 30 ml of 3.4 M
GO solution (100 mmol) and 10 ml 37% formaldehyde (100 mmol).
The mixture was heated at 65‡C, with additional GO and formalde-
hyde (50 mmol each) added 8 times at hourly intervals. MOLD was
prepared similarly, except that the reaction was conducted at 37‡C.
After 30 h, products were deformylated by mixing with one-half vol-
ume of concentrated HCl (¢nal concentration: 4 M HCl) and heating
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for 2 h at 100‡C. Amino acid analysis of an aliquot of the hydrolysate
indicated 40^50% conversion of 15N2-fL to GOLD or MOLD. The
resulting brown solutions were dried by centrifugal evaporation and
redissolved in distilled water. The majority of the brown contaminants
were removed by applying the aqueous solution to a Supelco C-18
cartridge (3 ml) and eluting with 30% acetonitrile in water. To isolate
basic compounds, the eluate was evaporated and dissolved in distilled
water (5 ml), then applied to a 1 ml column of SP-Sephadex (Phar-
macia), equilibrated with distilled water. The column was washed with
20 ml of 0.05 M HCl, then GOLD or MOLD eluted with 5 ml of 1 M
HCl. After drying by centrifugal evaporation and dissolving in amino
analysis bu¡er, the GOLD and MOLD were applied to a cation ex-
change amino acid analysis system and fractions containing the cross-
links were collected, desalted on Dowex-50-H, and dried. The puri-
ties of GOLD and MOLD (s 85%) were checked by amino acid
analyzer. The only detectable contaminants were ammonia and free
lysine.
2.2. Patients
Serum samples were obtained from 30 subjects: 15 chronic renal
failure (CRF) patients (six males and nine females with non-diabetic
nephropathy; mean age, 58 þ 4 years); and 15 normal controls (eight
males, seven females; mean age, 55 þ 5 years). The serum levels of
creatinine in uremic patients and healthy subjects were 11.3 þ 0.5
mg/dl (mean þ S.D., n = 15) and 0.5 þ 0.3 mg/dl (n = 15), respectively.
2.3. Sample preparation
To quantify protein-bound GOLD and MOLD in human serum,
the enzyme digested samples were prepared as previously described
[10,23]. Brie£y, to 1 ml plasma from each patient, 1 ml cold 10%
trichloroacetic acid was added and mixed. Precipitated proteins were
pelleted by centrifugation, and then 2 ml diethyl ether was added to
the pellet and mixed. Ether layer was separated by centrifugation and
the resultant pellet was dried for lyophilization. To 10 mg of lyophi-
lized protein from each sample, 0.02 mg peptidase (Sigma, from por-
cine intestine, 2%, w/w) was added in 1 ml PBS and incubated for 16 h
at 37‡C in a shaker incubator. Secondary digestion was continued for
additional 8 h with the addition of di¡erent peptidase (Sigma, from
Streptomyces griseus, 2%, w/w). The last digestion was achieved by the
addition of pronase E (Sigma, 2%, w/w, 16 h). After digestion, sam-
ples were ¢ltered through a 0.22 Wm ¢lter (Millipore, USA) for ESI/
MS/MS analysis. Recovery of 15N4-GOLD and 15N4-MOLD spiked
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Fig. 1. ESI mass spectra of GOLD (glyoxallysine dimer), MOLD
(methylglyoxallysine dimer), 15N4-GOLD and 15N4-MOLD.
Fig. 2. ESI/SIM chromatograms of uremic sera (a-1, -2); normal sera (b-1, -2); standards (c-1, -2). (a-1), (b-1) and (c-1) show GOLD, and (a-
2), (b-2) and (c-2) show MOLD. 15N4-GOLD and 15N4-MOLD, used as internal standards, show peaks at m/z 331 and m/z 345, respectively.
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into protein samples at a concentration of 500 ng/ml was 97.5 þ 4.8%
(mean þ S.E.M., n = 4).
2.4. Mass spectrometry
GOLD and MOLD were resolved by reversed-phase high perform-
ance liquid chromatography (RP-HPLC) and analyzed by ESI/MS/
MS using a TSQ 7000 triple quadrupole mass spectrometer (Finnigan
MAT Instruments, USA). RP-HPLC was conducted on a Monitor C-
18M column (5 mm, 150U4.6 mm ID, Column Engineering, USA)
equilibrated with solvent A (0.03% TFA in H2O), and eluted with a
linear gradient to 50% solvent B (40% acetonitrile, 60% H2O, 0.02%
TFA) during the ¢rst 30 min; the column was then washed with 50%
B for 20 min, with 100% B for 5 min, then re-equilibrated in 100%
solvent A for 20 min; £ow rate was 0.3 ml/min. Elution times for
GOLD and MOLD were approximately 8 and 13 min. For MS/MS
analysis, the ionizing energy, spray current and voltage were 72 eV,
1.5 mA, and 4.5 kV, respectively. For quanti¢cation of GOLD and
MOLD, the protonated molecular ion intensities m/z 327/331 (GOLD/
15N4-GOLD) and m/z 341/345 (MOLD/15N4-MOLD) were compared
in the selected ion monitoring mode. GOLD and MOLD concentra-
tions were normalized as pmol/mg serum protein, measured by the
Lowry assay [24]. For con¢rmation of structure, daughter ions (pos-
itive ions) were monitored by selected reaction monitoring (SRM)
using a collision gas pressure of 2 mT helium and collision energy
of 325 eV.
2.5. Statistical analysis
Data were analyzed by the unpaired Student’s t-test and the results
are expressed as means þ S.D.
3. Results
Fig. 1 shows ESI full scan mass spectra of GOLD, MOLD,
15N4-GOLD and 15N4- MOLD. The spectra show the intact
protonated molecular ions, [M+H] for GOLD (m/z 327),
MOLD (m/z 341), 15N4-GOLD (m/z 331), and 15N4-MOLD
(m/z 345).
No signi¢cant fragment or adduct ions were found in the
ESI spectrum in the mass range from 100 to 700. Based on
measurement of their intense parent molecular ions (m/z 327
and 341), both GOLD and MOLD were detected in normal
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Fig. 3. ESI/MS/MS spectra of GOLD and MOLD in uremic sera (a-1, -2), normal sera (b-1, -2) and standard GOLD and MOLD (c-1, -2).
The structures proposed for the daughter ions are shown under the ¢gures.
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and uremic serum by ESI/SIM, and quanti¢ed by comparison
to the intensity (peak area) of m/z 331 and m/z 345 ions of the
parent ions in the internal standards.
Fig. 2 shows representative ESI/SIM chromatograms of
uremic sera (a-1, -2), normal serum (b-1, -2), and standards
(c-1, -2), illustrating the detection of GOLD and MOLD in
human serum proteins, and increased levels of these com-
pounds in serum proteins from uremic patients. Collision
gas induced dissociation of the parent ions of GOLD and
MOLD, m/z 327 and 341, respectively, yielded daughter ion
spectra with a base peak at m/z 69 and major fragment at m/z
198 for GOLD, and a base peak at m/z 84 and fragment ion
of m/z 213 for MOLD (Fig. 3). Despite some di¡erences in
relative ion intensities resulting from di¡erential ion suppres-
sion, daughter ion spectra characteristic of GOLD and
MOLD standards were readily apparent in products detected
in uremic and normal serum.
As shown in Fig. 4, when the daughter ions were measured
by selected reaction monitoring, the traces of the daughter
ions in GOLD and MOLD in serum samples closely followed
those of the daughter ions produced by GOLD and MOLD
standards, further supporting the speci¢city of the ESI/MS/
MS assay. Quantitative analyses by ESI/SIM (Fig. 5) showed
that GOLD and MOLD were present at similar levels in se-
rum proteins of control, non-uremic patients, and that they
were comparably increased by 4^5-fold in uremic patients.
4. Discussion
Both GO and MGO react with proteins by a variety of
pathways, leading to N-(carboxyalkyl)amino acids, imidazo-
lones and imidazolium salts [15,16,18^20].
Among these compounds, we have identi¢ed the crosslinks,
GOLD and MOLD, in serum proteins using a highly speci¢c
and sensitive assay, and shown that these compounds are
signi¢cantly increased in serum proteins from uremic patients.
Our estimates of MOLD are signi¢cantly lower than those of
Nagaraj et al. [21], however minor contaminants in protein
hydrolysates can contribute to the apparently higher concen-
trations of MOLD detected by HPLC alone. In contrast, the
LC/MS/MS method, which combines HPLC with selected ion
monitoring MS/MS, provides much greater speci¢city for de-
tection and quantitation of MOLD. Comparisons with pre-
vious studies indicate that GOLD and MOLD are present at
much higher concentrations in serum proteins than the £uo-
rescent crosslink pentosidine. Thus, levels of pentosidine in
serum proteins range from about 5 pmol/mg in normal to
25 pmol/mg in uremic serum [11], less than 10% the combined
concentrations of GOLD and MOLD in the same sources. At
this point, the imidazolium crosslinks constitute the primary
Maillard reaction crosslinks which have been measured in
plasma proteins.
As with pentosidine, the origin of GOLD and MOLD in
serum protein in uremia is unknown. Since glucose concen-
tration was not increased in the serum of patients studied in
this project, the increase in GOLD and MOLD cannot be
attributed to glucose. There were no signi¢cant di¡erence in
LDL concentration between the control and uremic groups.
Although there was a signi¢cant increase in serum triglycer-
ides in uremic patients [25,26], there was no signi¢cant corre-
lation (Ps 0.05) between these measurements and levels of
GOLD or MOLD. Overall, these results suggest a general
increase in oxidative stress in uremia, independent of changes
in blood glucose or lipids. It is possible that GOLD and
MOLD may be derived directly from GO and MGO in plas-
ma, but concentrations of these precursors in uremic plasma
are also unknown. Alternatively, they may be derived from
reactions of ascorbate or dehydroascorbate with proteins,
since both CML and CEL are formed from ascorbate under
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Fig. 4. ESI/SRM chromatograms of MOLD and GOLD in uremic sera (a-1, -2), normal sera (b-1, -2) and of natural GOLD and MOLD
standards. The m/z 327 and m/z 341 are the protonated molecular parent ion of GOLD and MOLD, respectively, and the m/z 198 and m/z 213
correspond to their major protonated daughter ions. Proposed structures are as shown in Fig. 3.
Fig. 5. Serum levels of GOLD and MOLD in uremic patients with
non-diabetic nephropathy and in normal subjects. Data represent
means þ S.D. for 15 patients. *P6 0.005.
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oxidative conditions [18]. In this case, an increase in the ratio
of dehydroascorbate:ascorbate in plasma in uremia, resulting
from increased oxidative stress, might predispose to the for-
mation of GOLD and MOLD. Finally, the increase in GOLD
and MOLD might occur at constant glycemia and triglycer-
idemia, by increased autoxidation of both carbohydrate and
lipid substrates as a result of a general increase in oxidative
stress or decrease in glutathione-dependent antioxidant de-
fenses in uremia. Measurement of blood concentrations of
GO and MGO, ratios of dehydroascorbate:ascorbate, and
evaluation of the e¡ects of supplementation with anti-oxi-
dants and glutathione precursors or enhancers (N-acetylcys-
teine or lipoic acid) may lead to an understanding of the
origin of increased GOLD and MOLD in uremia.
At this time, because of their low concentrations in serum
proteins, there is no reason to believe that GOLD and MOLD
in these proteins are of any direct pathological signi¢cance.
However, they are biomarkers of altered biochemistry in
uremia and an understanding of their biological and chemical
origin may lead to better appreciation of the underlying mech-
anisms of pathogenesis and to development of improved ther-
apeutic strategies for the management of uremic patients.
The use of ESI/MS/MS for measurement of these and other
Maillard products in plasma proteins will be important for
accurate, sensitive and speci¢c measurement of these and oth-
er chemical modi¢cations of plasma proteins during aging and
in disease.
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